Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled trial assesses the effects of daily trans-resveratrol 1000 mg for 90 days on serum estradiol and estrone, and on gene expression of estrogen receptor alpha/beta and sirtuins 1/3 in 80 postmenopausal women with CAD. Participants are randomly assigned to resveratrol or placebo and undergo clinical, nutritional, and laboratory assessments. The trial is conducted at InCor Heart Institute and affiliated centers in São Paulo, Brazil. Outcomes may clarify whether resveratrol influences hormonal and metabolic pathways in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Postmenopausal women;
* Diagnosed coronary artery disease;
* Stable coronary disease;

Exclusion Criteria:

* Hypo- or hyperthyroidism,
* Rheumatic disease,
* Use of alcohol,
* hepatic failure,
* renal failure
* hormone replacement therapy
* use of insulin

Where it's running

• Servico de Prevencao, Cardiopatia na Mulher e Reabilitacao Cardiovascular, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP,
  São Paulo, São Paulo, Brazil Recruiting

Study contacts

• Principal investigator: Antonio de Padua Mansur, PhD Incor — InCor Heart Institute
• Study coordinator: Antonio de Padua Mansur, PhD
• Email: apmansur@yahoo.com
• Phone: +551126615448

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TAVI and PCI vs SAVR and CABG in low- and intermediate-risk patients with severe aortic stenosis and CAD

  This observational study compares TAVI plus PCI to SAVR plus CABG for patients who have both severe aortic stenosis and coronary artery disease.

  Recruiting Alexandria University · Alexandria, Alexandira · NCT07926022

• Hop extract vs soy isoflavone for menopausal symptoms

  This study tests whether a full-spectrum hop extract helps reduce menopausal mood symptoms better than soy isoflavones in peri- and postmenopausal women.

  Recruiting Menoclinica by Palacios · Madrid, Madrid · NCT07904390

• Predicting Plaque Growth Using Blood Flow Stress Markers

  This study tests whether combining blood flow patterns in the heart arteries with how blood-flow–sensitive cells respond can help predict which plaques will grow in people with coronary artery disease.

  Recruiting Queen Mary University of London · London · NCT07864051

• Identifying Coronary Plaque Traits with Photon-counting CT and Multimodality Imaging

  This study tests whether advanced imaging can better identify risky artery plaques in people with stable angina.

  Recruiting Queen Mary University of London · London · NCT07864025

• Ashoka Bark and Shatavari for Menopause

  This 12-week study tests whether a daily Ashoka Bark and Shatavari supplement helps reduce menopausal symptoms in postmenopausal women compared with a placebo.

  Recruiting Vidya USA Corporation · New Port Richey, Florida · NCT07861295

• Lifestyle changes to ease menopausal symptoms, sleep problems, and anxiety

  Researchers are testing whether a structured lifestyle education program helps perimenopausal and postmenopausal women see fewer menopausal symptoms, better sleep, and less anxiety compared to usual care.

  Recruiting Konya Beyhekim Training and Research Hospital · Konya, Konya · NCT07860645

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.